A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors / 药学学报
Acta Pharmaceutica Sinica
; (12): 1227-1231, 2007.
Article
en Zh
| WPRIM
| ID: wpr-268200
Biblioteca responsable:
WPRO
ABSTRACT
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase, originally identified as a protein kinase by its ability to phosphorylate and inactivate glycogen synthase. It was found that the overexpression of GSK-3 is associated with some diseases, such as diabetes, Alzheimer disease and other neurodegenerative diseases. Some pharmacological inhibitors of GSK-3 have been demonstrated to mimic insulin signaling, adjust glycogen synthesis and glucose metabolism, and improve insulin resistance. So GSK-3 inhibitors are realized as a new approach of treating diabetes. This review summarizes current advances in research of GSK-3 inhibitors as a new therapeutic approach for diabetes.
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Fisiología
/
Glucemia
/
Resistencia a la Insulina
/
Transducción de Señal
/
Glucógeno Sintasa Quinasa 3
/
Usos Terapéuticos
/
Diabetes Mellitus
/
Quimioterapia
/
Inhibidores Enzimáticos
/
Enfermedad de Alzheimer
Límite:
Animals
/
Humans
Idioma:
Zh
Revista:
Acta Pharmaceutica Sinica
Año:
2007
Tipo del documento:
Article